Active, Not Recruiting
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
NCT05389449
- Conditions
- Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +8 more
- Locations
-
- Research Site Los Angeles, California, United States
- Research Site Chicago, Illinois, United States
- Research Site Baltimore, Maryland, United States
- Research Site Kansas City, Missouri, United States